Patents by Inventor Mari Haramoto

Mari Haramoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Selective anticancer chimeric peptides which bind transferrin receptor
    Patent number: 8940862
    Abstract: It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: January 27, 2015
    Assignees: Stella Pharma Corporation
    Inventors: Koji Kawakami, Masayuki Kohno, Tomohisa Horibe, Oumi Nakajima, Mari Haramoto, Liying Yang
  • Selective anticancer chimeric peptides which bind neuropilin receptor
    Patent number: 8940863
    Abstract: It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: January 27, 2015
    Assignees: Stella Pharma Corporation
    Inventors: Koji Kawakami, Masayuki Kohno, Tomohisa Horibe, Oumi Nakajima, Mari Haramoto, Liying Yang
  • SELECTIVE ANTICANCER CHIMERIC PEPTIDE
    Publication number: 20130274200
    Abstract: It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
    Type: Application
    Filed: April 5, 2013
    Publication date: October 17, 2013
    Inventors: Koji Kawakami, Masayuki Kohno, Tomohisa Horibe, Oumi Nakajima, Mari Haramoto, Liying Yang
  • SELECTIVE ANTICANCER CHIMERIC PEPTIDE
    Publication number: 20130274201
    Abstract: It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
    Type: Application
    Filed: April 5, 2013
    Publication date: October 17, 2013
    Inventors: Koji Kawakami, Masayuki Kohno, Tomohisa Horibe, Oumi Nakajima, Mari Haramoto, Liying Yang
  • Selective anticancer chimeric peptide comprising an EGF receptor-binding peptide and a cytotoxic peptide
    Patent number: 8436137
    Abstract: It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: May 7, 2013
    Inventors: Koji Kawakami, Masayuki Kohno, Tomohisa Horibe, Oumi Nakajima, Mari Haramoto, Liying Yang
  • SELECTIVE ANTICANCER CHIMERIC PEPTIDE
    Publication number: 20110319336
    Abstract: It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide targeting cancer cells which overexpress EGFR or the like using a binding peptide such as a peptide sequence binding to EGFR, and a lytic peptide sequence, thereby solving such an object. Particularly, by using a chimeric peptide including an EGF receptor-binding peptide or the like and a cytotoxic peptide, this object was solved.
    Type: Application
    Filed: December 3, 2009
    Publication date: December 29, 2011
    Applicant: UPSTREAM INFINITY, INC.
    Inventors: Koji Kawakami, Masayuki Kohno, Tomohisa Horibe, Oumi Nakajima, Mari Haramoto, Liying Yang